ClinicalTrials.gg

Program

neladalkib

In GlaxoSmithKline's pipeline, Brain-penetrant anaplastic lymphoma kinase (ALK)-selective tyrosine kinase inhibitor (TKI). Its studies are mostly in Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung, led by GlaxoSmithKline.

Furthest: phase 3, since Nov 8, 20242 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline22 open or runningphase 3since Nov 8, 2024May 17, 2022Dec 2027phase 2 · NCT05384626
  • Named in GlaxoSmithKline’s own pipeline as neladalkib GSK6739060, phase 4, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 17, 2022First study: phase 2 study in Neoplasm MetastasisFirst studyNCT05384626 · 840 planned · United States, Australia, Belgium and more
  2. Nov 8, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06765109 · 450 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 2027Primary completion: phase 2 study in Neoplasm MetastasisNCT05384626
  2. Dec 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06765109

TargetBeta

“Brain-penetrant anaplastic lymphoma kinase (ALK)-selective tyrosine kinase inhibitor (TKI)”the company's pipeline, read by Claude · source

Other programs on ALK

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431
lorlatinibrulePfizerphase 420
gilteritinibruleAstellas Pharmaphase 320
ensartinibruleBetta Pharmaceuticalsphase 312
repotrectinibruleBristol-Myers Squibbphase 39
Foritinib SuccinateFosun Pharmaphase 21
ALK Molecular Glue Degrader TRI-611ruletriana-biomedicines-incphase 21
AQUA07Hoffmann-La Rochephase 11
SIM0518ruleSimcere Pharmaceutical Groupphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06765109Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingDec 2029450
NCT05384626Neoplasm Metastasis · United States, Australia, Belgium and more2RecruitingDec 2027840

How it is read

Names in the registry

  • “Neladalkib (NVL-655)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.